Details
Stereochemistry | ACHIRAL |
Molecular Formula | C19H18F3N3O2 |
Molecular Weight | 377.3603 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1CCC(CC1)C(=O)C2=CC=CC(NC(=O)C3=C(F)C=C(F)C=C3F)=N2
InChI
InChIKey=XEDHVZKDSYZQBF-UHFFFAOYSA-N
InChI=1S/C19H18F3N3O2/c1-25-7-5-11(6-8-25)18(26)15-3-2-4-16(23-15)24-19(27)17-13(21)9-12(20)10-14(17)22/h2-4,9-11H,5-8H2,1H3,(H,23,24,27)
Molecular Formula | C19H18F3N3O2 |
Molecular Weight | 377.3603 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1805 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20855361 |
2.1 nM [Ki] |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
526.15 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT03465436 |
400 mg single, oral dose: 400 mg route of administration: oral experiment type: single co-administered: |
LASMIDITAN plasma | Homo sapiens population: healthy age: sex: food status: |
|
322.8 ng/mL |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
LASMIDITAN serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
394.7 ng/mL |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
LASMIDITAN serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3189.08 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT03465436 |
400 mg single, oral dose: 400 mg route of administration: oral experiment type: single co-administered: |
LASMIDITAN plasma | Homo sapiens population: healthy age: sex: food status: |
|
1892 ng × h/mL |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
LASMIDITAN serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
2244 ng × h/mL |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
LASMIDITAN serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000ClinPharmR.pdf#page=18 Page: 18.0 |
low | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000ClinPharmR.pdf#page=18 Page: 18.0 |
low | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000ClinPharmR.pdf#page=18 Page: 18.0 |
low | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000ClinPharmR.pdf#page=18 Page: 18.0 |
low | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000ClinPharmR.pdf#page=18 Page: 18.0 |
low | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000ClinPharmR.pdf#page=18 Page: 18.0 |
low | |||
low | no (co-administration study) Comment: "when administered with sumatriptan, no change in sumatriptan PK was observed; '""low potential of interactions""" Page: 8, 18 |
|||
Page: 8.0 |
no | |||
Page: 8.0 |
no | |||
Page: 8.0 |
no | |||
Page: 8.0 |
no | |||
Page: 8.0 |
no | |||
Page: 8.0 |
no | no (co-administration study) Comment: administered with caffeine, daily dosing of lasmiditan did not alter PK of caffeine Page: 8.0 |
||
Page: 8.0 |
no | no (co-administration study) Comment: administered with caffeine, daily dosing of lasmiditan did not alter PK of caffeine Page: 8.0 |
||
Page: 8.0 |
no | no (co-administration study) Comment: administered with tolbutamide, daily dosing of lasmiditan did not alter the PK of tolbutamide. Page: 8.0 |
||
Page: 8.0 |
no | no (co-administration study) Comment: administered with tolbutamide, daily dosing of lasmiditan did not alter the PK of tolbutamide. Page: 8.0 |
||
Page: 8.0 |
no | no (co-administration study) Comment: administered with midazolam, daily dosing of lasmiditan did not alter PK of midazolam Page: 8.0 |
||
Page: 8.0 |
no | no (co-administration study) Comment: administered with midazolam, daily dosing of lasmiditan did not alter PK of midazolam Page: 8.0 |
||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000ClinPharmR.pdf#page=37 Page: 37.0 |
yes [IC50 85 uM] | |||
yes [Ki 20.7 uM] | ||||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000ClinPharmR.pdf#page=16 Page: 16.0 |
yes | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000ClinPharmR.pdf#page=18 Page: 18.0 |
yes | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000ClinPharmR.pdf#page=18 Page: 18.0 |
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 8.0 |
no | |||
Page: 8.0 |
no | |||
Page: 8.0 |
no | |||
Page: 8.0 |
no | |||
Page: 8.0 |
no | |||
Page: 8.0 |
no | |||
Page: 8.0 |
no | |||
Page: 8.0 |
no | |||
Page: 8.0 |
no | |||
Page: 8.0 |
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000ClinPharmR.pdf#page=18 Page: 18.0 |
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20855361
Lasmiditan in vitro binding studies show a Ki value of 2.21 nM at the 5-HT(1F) serotonin receptor, compared with Ki values of 1043 nM and 1357 nM at the 5-HT(1B) and 5-HT(1D) receptors, respectively. Lasmiditan did not contract rabbit saphenous vein rings, a surrogate assay for human coronary artery constriction, at concentrations up to 100 uM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:35:00 GMT 2025
by
admin
on
Mon Mar 31 18:35:00 GMT 2025
|
Record UNII |
760I9WM792
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
DEA NO. |
2790
Created by
admin on Mon Mar 31 18:35:00 GMT 2025 , Edited by admin on Mon Mar 31 18:35:00 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
760I9WM792
Created by
admin on Mon Mar 31 18:35:00 GMT 2025 , Edited by admin on Mon Mar 31 18:35:00 GMT 2025
|
PRIMARY | |||
|
9176
Created by
admin on Mon Mar 31 18:35:00 GMT 2025 , Edited by admin on Mon Mar 31 18:35:00 GMT 2025
|
PRIMARY | |||
|
LASMIDITAN
Created by
admin on Mon Mar 31 18:35:00 GMT 2025 , Edited by admin on Mon Mar 31 18:35:00 GMT 2025
|
PRIMARY | |||
|
760I9WM792
Created by
admin on Mon Mar 31 18:35:00 GMT 2025 , Edited by admin on Mon Mar 31 18:35:00 GMT 2025
|
PRIMARY | |||
|
11610526
Created by
admin on Mon Mar 31 18:35:00 GMT 2025 , Edited by admin on Mon Mar 31 18:35:00 GMT 2025
|
PRIMARY | |||
|
100000172980
Created by
admin on Mon Mar 31 18:35:00 GMT 2025 , Edited by admin on Mon Mar 31 18:35:00 GMT 2025
|
PRIMARY | |||
|
CHEMBL3039520
Created by
admin on Mon Mar 31 18:35:00 GMT 2025 , Edited by admin on Mon Mar 31 18:35:00 GMT 2025
|
PRIMARY | |||
|
DTXSID40469435
Created by
admin on Mon Mar 31 18:35:00 GMT 2025 , Edited by admin on Mon Mar 31 18:35:00 GMT 2025
|
PRIMARY | |||
|
m12168
Created by
admin on Mon Mar 31 18:35:00 GMT 2025 , Edited by admin on Mon Mar 31 18:35:00 GMT 2025
|
PRIMARY | |||
|
DB11732
Created by
admin on Mon Mar 31 18:35:00 GMT 2025 , Edited by admin on Mon Mar 31 18:35:00 GMT 2025
|
PRIMARY | |||
|
5351
Created by
admin on Mon Mar 31 18:35:00 GMT 2025 , Edited by admin on Mon Mar 31 18:35:00 GMT 2025
|
PRIMARY | |||
|
ZZ-66
Created by
admin on Mon Mar 31 18:35:00 GMT 2025 , Edited by admin on Mon Mar 31 18:35:00 GMT 2025
|
PRIMARY | |||
|
C166996
Created by
admin on Mon Mar 31 18:35:00 GMT 2025 , Edited by admin on Mon Mar 31 18:35:00 GMT 2025
|
PRIMARY | |||
|
Lasmiditan
Created by
admin on Mon Mar 31 18:35:00 GMT 2025 , Edited by admin on Mon Mar 31 18:35:00 GMT 2025
|
PRIMARY | |||
|
2256930
Created by
admin on Mon Mar 31 18:35:00 GMT 2025 , Edited by admin on Mon Mar 31 18:35:00 GMT 2025
|
PRIMARY | |||
|
439239-90-4
Created by
admin on Mon Mar 31 18:35:00 GMT 2025 , Edited by admin on Mon Mar 31 18:35:00 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TRANSPORTER -> SUBSTRATE |
In vitro studies showed that lasmiditan is a substrate of P-gp. However, lasmiditan is a BCS Class I drug and is unlikely to be affected by P-gp inhibitors.
|
||
|
EXCRETED UNCHANGED |
AMOUNT EXCRETED
URINE
|
||
|
TRANSPORTER -> INHIBITOR |
Lasmiditan is an in-vitro inhibitor of P-gp and BCRP.
|
||
|
TRANSPORTER -> INHIBITOR |
Lasmiditan is an in-vitro inhibitor of P-gp and BCRP.
|
||
|
BINDER->LIGAND |
The human plasma protein binding of lasmiditan is approximately 55% to 60% and independent of concentration between 15 and 500 ng/mL.
BINDING
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
Biological Half-life | PHARMACOKINETIC |
|
|
|||
Tmax | PHARMACOKINETIC |
|
ORAL ADMINISTRATION |
|
||